Breast Cancers Today Videos

Advertisement
Rebecca Shatsky, MDHR Breast Cancer | June 18, 2025
New drugs like vepdegestrant and oral SERDs may reshape HR+ breast cancer treatment with novel mechanisms and CDK4/6 combos.
David M. Waterhouse, MD, MPHTriple-Negative Breast Cancer | June 17, 2025
Dr. David Waterhouse discusses geographic barriers to TNBC trials for Black women and the case for decentralized research.
Sibylle Loibl, MDHER2 Breast Cancer | June 18, 2025
DESTINY-Breast09 shows promising PFS with T-DXd + pertuzumab vs THP in HER2+ MBC, but safety and sequencing raise questions.
Hatem Soliman, MDTriple-Negative Breast Cancer | June 12, 2025
TVEC plus chemo shows promise in early TNBC, boosting immune response and survival with favorable safety profile.
Debra Patt, MD, PhD, MBABreast Cancer News | June 12, 2025
Dr. Patt discusses how AI is transforming oncology care, and how to implement it responsibly and effectively.
Sarah Sammons, MDHR Breast Cancer | June 12, 2025
Dr. Sammons on RLY-2608 plus fulvestrant in HR+/HER2– mBC with PIK3CA mutations: safety, efficacy, and trial updates.
Rebecca Shatsky, MDHER2 Breast Cancer | June 10, 2025
Dr. Shatsky weighs DESTINY-Breast09 findings and highlights the need to balance efficacy with long-term quality of life.
Erika P. Hamilton, MDTriple-Negative Breast Cancer | June 9, 2025
Emi-Le ADC shows promising activity in B7-H4–positive TNBC and endometrial cancer with a novel auristatin payload.
Sibylle Loibl, MDHR Breast Cancer | June 9, 2025
INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.
Antonio Llombart Cussac, MD, PhDHR Breast Cancer | June 11, 2025
ADELA trial explores elacestrant + everolimus for ESR1-mutated breast cancer post-CDK4/6, aiming to boost 2L outcomes.
Rebecca Shatsky, MDTriple-Negative Breast Cancer | June 9, 2025
New ASCENT-04 data could shift first-line care in PD-L1+ TNBC. Dr. Rebecca Shatsky shares real-world insights from ASCO 2025.
Rupert Bartsch, MDHER2 Breast Cancer | June 6, 2025
HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.
Sara Tolaney, MD, MPHTriple-Negative Breast Cancer | June 6, 2025
Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Erika P. Hamilton, MDHR Breast Cancer | June 6, 2025
Vepdegestrant improves PFS in ESR1-mutant ER+/HER2- breast cancer, offering a well-tolerated oral option post-CDK4/6.
Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 5, 2025
Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.
Stephanie L. Graff, MDHER2 Breast Cancer | June 5, 2025
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
Eva Blondeaux, MDGenetics & Breast Cancer | May 22, 2025
Dr. Eva Blondeaux discusses RRSO timing and fertility in young BRCA+ women and the need for shared, personalized decisions.
Eva Blondeaux, MDGenetics & Breast Cancer | May 22, 2025
Risk-reducing surgery improves survival in young BRCA1/2 carriers, study shows, guiding counseling for high-risk patients.
Advertisement